Appendix listing investments of New Leaf Ventures II, L.P. (2014)
Appendix listing investments of New Leaf Ventures II, L.P. (2014) The document provides a detailed but routine financial snapshot of a private venture fund’s portfolio, listing companies, investment amounts, and performance metrics. It contains no direct references to high‑profile officials, government agencies, or controversial transactions, limiting its investigative usefulness. While the data could support background research on specific biotech firms, it lacks actionable leads, novel revelations, or links to powerful actors. Key insights: Shows realized and unrealized investments across therapeutic, diagnostics, and healthcare device companies.; Highlights very high multiples on a few investments (e.g., Epizyme, Intercept Pharmaceuticals).; Provides cost, value, and IRR figures for each portfolio company as of March 31, 2014.
Summary
Appendix listing investments of New Leaf Ventures II, L.P. (2014) The document provides a detailed but routine financial snapshot of a private venture fund’s portfolio, listing companies, investment amounts, and performance metrics. It contains no direct references to high‑profile officials, government agencies, or controversial transactions, limiting its investigative usefulness. While the data could support background research on specific biotech firms, it lacks actionable leads, novel revelations, or links to powerful actors. Key insights: Shows realized and unrealized investments across therapeutic, diagnostics, and healthcare device companies.; Highlights very high multiples on a few investments (e.g., Epizyme, Intercept Pharmaceuticals).; Provides cost, value, and IRR figures for each portfolio company as of March 31, 2014.
Tags
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.